AnchorDx

CA - FremontBiotechnology1 H-1B visas (FY2023)

Focus: AnchorDx is a early-stage biotechnology company developing high-throughput sequencing platforms for oncology diagnostics, with a focus on liquid and tissue-based biomarker assays. Founded in 2019 and based in Fremont, CA, the company is pre-revenue and operates at the intersection of precision oncology and molecular diagnostics.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About AnchorDx

AI assessmentNot Hiring

No open roles listed right now. Follow AnchorDx to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

UriFind Bladder Cancer Assay

Bladder Cancer

N/A

Clinical Trials (1)

NCT05643690Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay

N/A

Help build intelligence for AnchorDx

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a pre-revenue company with three clinical-stage oncology assays in development, offering equity upside potential
Specialized focus on high-throughput sequencing and DNA methylation biomarkers addresses high-unmet need in lung and bladder cancer detection
Early-stage hiring (1 active role, minimal team) suggests foundational phase where early employees shape culture and impact

Watch Out For

No revenue, financials, or funding data disclosed—financial runway and sustainability unclear; cash position unknown limits ability to assess burn rate
Minimal public presence: zero publications and no recent news suggests early stealth phase with limited validation or clinical traction
Extremely lean organization (1 open role in IT) indicates very early stage with limited team depth, mentorship, and career development structure

Generated by Claude from AnchorDx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Urine DNA Methylation/Somatic Mutation Profiling Assay

Urothelial Carcinoma

N/A

Clinical Trials (1)

NCT04314245Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma

N/A

Active Comparator: Surgery Pathology or Cystoscopy

Upper Tract Urothelial Carcinoma

N/A

Clinical Trials (1)

NCT04948528Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for Upper Tract Urothelial Carcinoma Detection

N/A

ctDNA methylation analysis by NGS

Pulmonary Nodules

N/A

Clinical Trials (1)

NCT03651986Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules

N/A

A genomic and transcriptomic landscape analysis

Pulmonary Nodules

N/A

Circulating Tumor DNA Methylation Test

Pulmonary Nodule

N/A

Clinical Trials (1)

NCT03181490Circulating Tumor DNA Methylation Test to Differentiate Benign and Malignant Pulmonary Nodules

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2019

Portfolio: 5 clinical trials

Top TAs: Oncology, Respiratory

H-1B (2023): 1 approval

Therapeutic Area Focus

Oncology

3 pipeline

Respiratory

2 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo